scholarly journals Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

2020 ◽  
Vol 7 (3) ◽  
pp. HEP27 ◽  
Author(s):  
Abdalla Aly ◽  
Sarah Ronnebaum ◽  
Dipen Patel ◽  
Yunes Doleh ◽  
Fernando Benavente
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Poor Quality ◽  
Disease Stage ◽  
The Usa ◽  
Humanistic Burden

Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008–2018 were systematically searched. Results: HCC incidence was 9.5 per 100,000 person-years in most recent data, but was ∼100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25–77% of patients did not receive surgical, locoregional or systemic treatment. Conclusion: Better treatments are needed to extend survival and improve quality of life for patients with HCC.

503 QUALITY OF LIFE AS A PREDICTOR OF POST-ESOPHAGECTOMY SHORT TERM OUTCOMES AND SURVIVAL

2020 ◽  
Vol 33 (Supplement_1) ◽  
Author(s):  
A Katz ◽  
J Ramirez-GraciaLuna ◽  
A Kammili ◽  
F Abureida ◽  
J Cools-Lartigue ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Operative Mortality ◽  
Advanced Disease ◽  
Locally Advanced ◽  
Stage I ◽  
Disease Stage ◽  
Clinical Staging ◽  
Term Survival ◽  
Locally Advanced Disease

Abstract   Most esophageal cancer patients present with symptoms that impact quality of life (QOL). In this study, we sought to determine the influence of QOL at diagnosis on postoperative outcomes and survival (OS). Methods A prospectively-collected esophagectomy database (2006–17) was queried to identify patients who completed Functional Assessment of Cancer Therapy-Esophageal module (FACT-E). Demographics/tumor/treatment details, operative variables, complications and OS were collected. Statistical analysis was done using Cox regression, logistic regression, ANOVA or Chi-square tests. Results Of 647 patients underwent esophagectomy in the study period, 359 how completed FACT-E at diagnosis were included in the study (age 64 ± 11, male 82%, stage I:9%, II:15%, III:69%, IV:7%, adenocarcinoma: 78%, neoadjuvant therapy: 70%). Clinical stage I was associated with better QOL at diagnosis (131 ± 2 vs 118 ± 28, p < 0.02). FACT-E > 125 was associated with lower peri-operative mortality (9% vs 1%, 0R = 6.1, P = 0.01), and when divided into quintiles, correlated directly with OS (Figure 1a), more over it was able to prognostically differentiate patients with locally-advanced disease (stage II + III) (Figure 1b) better than the clinical staging (Figure 1c). Conclusion QOL at diagnosis predicts peri-operative mortality and long-term survival. It can help to prognostically differentiate between patients with locally advanced disease. Attempts to improve QOL prior to surgery, such as with pre-habilitation, remain an attractive area of investigation.

scholarly journals Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma

Oncoreview ◽  
2021 ◽  
Vol 11 (3(43)) ◽  
pp. 77-79
Author(s):  
Wojciech Rogowski ◽  
Przemysław Będkowski
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Survival Time ◽  
Response Rate ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Locally Advanced ◽  
Malignant Neoplasms ◽  
Metastatic Pancreatic Adenocarcinoma

Pancreatic cancer is one of the malignant neoplasms with the worst prognosis. It is most often diagnosed at an advanced stage, which relates to unsatisfactory results of the therapy. Only about 15–20% of patients with pancreatic cancer qualify for surgery. The remaining patients are diagnosed with locally advanced disease or much more frequently in the generalized stage. Systemic treatment (chemotherapy) remains the mainstay of therapy in these patients, but both the response rate and progression-free time are unsatisfactory [1, 2]. This paper presents a case of a patient with metastatic pancreatic cancer, in whom three lines of systemic treatment were applied sequentially, which allowed to extend the survival time and improve the quality of life.

Heart Transplantation - Part I: General Considerations

2020 ◽  
Author(s):  
Michael M. Givertz
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Heart Disease ◽  
Heart Transplantation ◽  
Structural Heart Disease ◽  
Poor Quality ◽  
Disease Stage ◽  
Circulatory Support ◽  
Stage D

Heart failure (HF) is a major public health problem with significant associated morbidity and mortality. In 2001, the American College of Cardiology/American Heart Association (ACC/AHA) guideline committee proposed a new approach to the classification of HF that emphasized both the development and progression of disease.  Stage A and B patients are at high risk for developing HF, and include those without structural heart disease (Stage A) and those with structural heart disease, but without signs or symptoms of HF (Stage B).  Stage C and D patients have structural heart disease with prior or current symptoms of HF (Stage C) or refractory HF requiring specialized interventions (Stage D).  Rregistries suggest that between 5% and 10% of patients with HF have advanced disease, which is associated with 1-year mortality in excess of 50% and a poor quality of life. The Heart Failure Society of America (HFSA) defines Stage D heart failure as “the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy…generally accompanied by frequent hospitalization, severely limited exertional tolerance, and poor quality of life.”  In this two-part chapter, we focus on heart transplantation, which remains the standard-of-care for highly selected patients with end-stage HF and absence of contraindications to transplant.1-5 This review contains 7 figures, 8 tables, and 46 references. Key words: heart failure, cardiomyopathy, heart transplant, mechanical circulatory support, prognosis, pulmonary hypertension, diabetes, HLA sensitization, donor

Mo1054 Poor Quality of Life in Patients With Hepatocellular Carcinoma Associated With Worse Prognosis

2014 ◽  
Vol 146 (5) ◽  
pp. S-996
Author(s):  
Adam Meier ◽  
Adam Yopp ◽  
Pragathi Kandunoori ◽  
Akbar K. Waljee ◽  
Jorge A. Marrero ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Poor Quality ◽  
Worse Prognosis

Heart Transplantation - Part I: General Considerations

2020 ◽  
Author(s):  
Michael M. Givertz
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Heart Disease ◽  
Heart Transplantation ◽  
Structural Heart Disease ◽  
Poor Quality ◽  
Disease Stage ◽  
Circulatory Support ◽  
Stage D

Heart failure (HF) is a major public health problem with significant associated morbidity and mortality. In 2001, the American College of Cardiology/American Heart Association (ACC/AHA) guideline committee proposed a new approach to the classification of HF that emphasized both the development and progression of disease.  Stage A and B patients are at high risk for developing HF, and include those without structural heart disease (Stage A) and those with structural heart disease, but without signs or symptoms of HF (Stage B).  Stage C and D patients have structural heart disease with prior or current symptoms of HF (Stage C) or refractory HF requiring specialized interventions (Stage D).  Rregistries suggest that between 5% and 10% of patients with HF have advanced disease, which is associated with 1-year mortality in excess of 50% and a poor quality of life. The Heart Failure Society of America (HFSA) defines Stage D heart failure as “the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy…generally accompanied by frequent hospitalization, severely limited exertional tolerance, and poor quality of life.”  In this two-part chapter, we focus on heart transplantation, which remains the standard-of-care for highly selected patients with end-stage HF and absence of contraindications to transplant.1-5 This review contains 7 figures, 8 tables, and 46 references. Key words: heart failure, cardiomyopathy, heart transplant, mechanical circulatory support, prognosis, pulmonary hypertension, diabetes, HLA sensitization, donor

scholarly journals Economic Burden and poor quality of life Associated With Acromegaly in the United States

2015 ◽  
Vol 18 (3) ◽  
pp. A59 ◽  
Author(s):  
S. Liu ◽  
Y. Xu ◽  
J. Sisco ◽  
S.M. Begelman ◽  
L. Shi
Keyword(s):  
Quality Of Life ◽  
United States ◽  
Economic Burden ◽  
The United States ◽  
Poor Quality

scholarly journals Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab

2018 ◽  
Vol 12 ◽  
pp. 117822341875803 ◽  
Author(s):  
John Syrios ◽  
Evelina Pappa ◽  
Nikolaos Volakakis ◽  
Anastasios Grivas ◽  
John Alafis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Advanced Disease ◽  
Negative Impact ◽  
Disease Stage ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Purpose: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (anti-HER2) antibody delivered intravenously, has revolutionized the treatment of patients with breast cancer overexpressing HER2 protein. Recently, a newer subcutaneous formulation was shown to have comparable efficacy to the initial intravenous trastuzumab. In this study, we aimed to evaluate the impact of subcutaneous trastuzumab on the health-related quality of life (HRQoL) of patients diagnosed with early or metastatic HER2-overexpressing breast cancer. Methods: Patients were provided with the EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) and the BR-23 questionnaires. The scoring of questionnaires and patient’s sociodemographic and clinicopathologic characteristics were recorded and analyzed by descriptive and correlation statistics employing t test and 2-way analysis of variance. Results: A total of 163 patients agreed to participate in the study. About 90 of 163 patients (55.21%) received subcutaneous trastuzumab and 21 patients intravenous trastuzumab (12.88%). A control group of 52 HER2+ patients received chemotherapy without trastuzumab (31.90%). Patients receiving subcutaneous trastuzumab were older and of more advanced disease stage compared with those receiving chemotherapy (58.5 vs 51 years, 39.8% vs 28.8% advanced disease). In univariate analysis, subcutaneous trastuzumab was associated with less nausea and vomiting ( P = .002) but worse cognitive function ( P = .013) and dyspnea ( P = .042). Patients who have received >8 cycles of subcutaneous trastuzumab reported less diarrhea ( P = .049) and systemic therapy side effects ( P = .015). Multivariate analysis showed that patients without comorbidity receiving subcutaneous trastuzumab had less treatment side effects, less upset by hair loss, and higher emotional functioning. Of note, mastectomy and subcutaneous trastuzumab were associated with improved role functioning ( P = .021). In metastatic disease, no negative impact of subcutaneous trastuzumab on HRQoL was found. Conclusions: The administration of subcutaneous trastuzumab improved certain symptoms and did not adversely affect most of the assessed functional scales. Particularly, in the metastatic setting, subcutaneous trastuzumab had no negative impact on HRQoL.

Predictors of Health-Related Quality of Life in Hepatocellular Carcinoma

2009 ◽  
Author(s):  
Leigh A. Gemmell ◽  
T. Clark Gamblin ◽  
Jennifer M. Hammond ◽  
Sonja Likumahuwa ◽  
Richard Schulz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

KUALITAS HIDUP PASIEN STROKE DI POLIKLINIK RAWAT JALAN RUMAH SAKIT SWASTA YOGYAKARTA

2019 ◽  
Vol 7 (3) ◽  
pp. 232-237
Author(s):  
Hana Larasati ◽  
Theresia Titin Marlina
Keyword(s):  
Quality Of Life ◽  
Social Relations ◽  
Hemorrhagic Stroke ◽  
Poor Quality ◽  
Social Dimension ◽  
Stroke Patients ◽  
Sampling System ◽  
Post Stroke ◽  
Psychological Dimension

Background: stroke is a disorder of nervous system function that occurs suddenly and is caused by brain bleeding disorders that can affect the quality of life physical dimensions, social dimensions, psychological dimensions, environmental dimensions. Based on the result of Lumbu study (2015) the number of samples were 71 people collected data using the (WHOQOL-BREF). There were 56 people (78,9%) had the poor quality of life of post stroke. The mean of post-stroke quality of life domain was physical domain (45,27%), psychological domain (49,87%), social relations domain (48,15%) and environmental domain (50.01%). Objective: the purpose of the study was know the quality of life of the stroke patients in Outpatient Polyclinic of Private Hospital in Yogyakarta. Methods: used descriptive quantitative by using questionnaire test of purposive sampling system based on patients who have been affected of ischemic or hemorrhagic stroke before, number 30 respondents. Result: quality of life of stroke patient of medium physical dimension (67%), psychological dimension (71%), social dimension (67%), dimension good environment (63%). Conclusion: the quality of life of stroke patients of physical dimension, psychological dimension, and moderate social dimension, while the quality of life of stroke patients were good environmental dimension.   Keywords: Hemorrhagic stroke, ischemic stroke, quality of life

Sign in / Sign up

Export Citation Format

Share Document